Abivax SA（ABVX）财务数据ABVXAbivax SA

Evaluating the bottom line, Abivax SA maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -381.74%, provide a clear picture of how effectively ABVX converts its operational activities into shareholder value.

In the context of the broader market, ABVX competes directly with industry leaders such as BHC and CRON. With a market capitalization of $8.08B, it holds a leading position in the sector. When comparing efficiency, ABVX's gross margin of N/A stands against BHC's 65.04% and CRON's 53.69%. Such benchmarking helps identify whether Abivax SA is trading at a premium or discount relative to its financial performance.

The company reported a last earnings EPS of -1.7100, which was a 58.33% surprise to the downside, reflecting challenges in profitability. The forward EV to EBITDA is -1.209165, indicating potential issues in cash flow generation.